首页 | 官方网站   微博 | 高级检索  
     

自体外周血单核细胞移植治疗重度下肢缺血的临床疗效
引用本文:方征东,王晓天,胡何节,孙小杰,葛新宝,程灿.自体外周血单核细胞移植治疗重度下肢缺血的临床疗效[J].中国临床保健杂志,2017,20(4):345-348.
作者姓名:方征东  王晓天  胡何节  孙小杰  葛新宝  程灿
作者单位:;1.安徽医科大学附属省立医院血管外科
基金项目:安徽省自然科学基金(1408085MH177);安徽省公益性技术应用研究联动计划(1704f0804013)
摘    要:目的探讨自体外周血单核细胞治疗重度下肢缺血的长期疗效和安全性。方法回顾性分析行自体外周血单核细胞治疗的重度下肢缺血患者的临床资料。根据引起下肢缺血的原因,患者分为2组:动脉硬化闭塞(ASO)组,共29例;血栓闭塞性脉管炎(TAO)组,共43例。采用临床症状及下肢血流改变进行疗效评价,随访所有患者治疗后3年内疗效及不良反应情况。结果 ASO组患者临床症状评分和血流灌注参数在6个月内明显改善,但随着随访时间延长又逐渐恶化至术前水平;TAO组患者临床症状评分和血流灌注参数在改善后能得到长时间维持(P0.05)。随访结束,ASO组免截肢率为17.2%,TAO组免截肢率为65.1%(F=15.99,P0.05)。结论自体外周血单核细胞移植是治疗重度下肢缺血安全、有效的方法,适合于血栓闭塞性脉管炎引起的重度下肢缺血。

关 键 词:闭塞性动脉硬化  闭塞性血栓性脉管炎  下肢  细胞移植  单核细胞
收稿时间:2017/4/11 0:00:00

Clinical analysis of autologous peripheral blood mononuclear cells for treating critical limb ischemia
Fang Zhengdong,Wang Xiaotian,Hu Hejie,Sun Xiaojie,Ge Xinbao and Cheng Can.Clinical analysis of autologous peripheral blood mononuclear cells for treating critical limb ischemia[J].Chinese JOurnal of Clinical Healthcare,2017,20(4):345-348.
Authors:Fang Zhengdong  Wang Xiaotian  Hu Hejie  Sun Xiaojie  Ge Xinbao and Cheng Can
Affiliation:Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China,Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China,Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China,Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China,Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China and Department of Vascular Surgery,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,China
Abstract:ObjectiveTo evaluate long-term clinical outcomes after autologous peripheral blood mononuclear cells(PBMNC) implantation in patients with critical limb ischemia(CLI).Methods The clinical data of 72 patients with CLI were analyzed retrospectively.There were 29 patients with arteriosclerosis(ASO) and 43 patients with thromboangiitis obliterans(TAO).A series of clinical outcomes and laboratory findings were compared between the ASO and TAO group.ResultsIn patients with ASO,clinical symptoms,ankle brachial pressure index(ABI)and transcutaneous oxygen pressure(TcpO2) improved after 1 month,but gradually decreased during 3-year follow-up and returned to baseline levels.In TAO group,clinical symptoms,ABI and TcpO2 were significantly increased after 1 month and remained high during 3-year follow-up.The amputation-free rates after PBMNC implantation were 17.2% in ASO group and 61.5% in TAO group.ConclusionsPBMNC implantation is safe and effective in patients with CLI.Compared with ASO,PBMNC implantation is more effective in CLI patients with TAO disease.
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《中国临床保健杂志》浏览原始摘要信息
点击此处可从《中国临床保健杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号